A global leader in in vitro diagnostics for over 55 years, bioMérieux has always been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. The Company is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. It provides diagnostic solutions that improve patient health and ensure consumer safety.
bioMérieux develops and produces in vitro diagnostic solutions (systems, reagents, software and services) for private and hospital laboratories, mainly for the diagnosis of infectious diseases. The results obtained from a patient sample (blood, urine, stool, cerebrospinal fluid, saliva, etc.) provide doctors with information to support their decisions.
For 25 years, bioMérieux has also applied the expertise acquired in the clinical sector to meeting industrial microbiology needs, making it possible to manage contamination risks in agri-food, pharmaceutical and cosmetic products, at each step of the production chain.
- € 3.1 billion in sales (as of Dec. 31,2020)
- 2 main applications:
- Clinical Diagnostics: ~ 85% of sales,
- Industrial Microbiology: ~ 15% of sales.
- 12,800 employees (full-time equivalents) at the end of December 2020.
- Present 44 countries and serves more than 160 countries with the support of a large network of distributors;
- Over 93% of international sales.
- 15 main production sites.
- 17 R&D sites.
-
bioMérieux is listed on NYSE Euronext Paris.
| Name | Type | Size | Download |
|---|---|---|---|
| argene_pcr_test_kits.pdf | 431.34 KB | ||
| walkaway_sample_processing_system.pdf | 211.36 KB | ||
| aps_one_-automatic_plate_pouring_system.pdf | 25.53 KB |
